Celebrity couples used the 2025 iHeartRadio Music Awards—hosted by LL Cool J March 17—as a beautiful date night. See who all showed up and showed out on the red carpet. Hosted by LL Cool J ...

So, what’s really going on? In early 2023, the U.S. Food and Drug Administration (FDA) granted accelerated approval to a new Alzheimer’s drug called Leqembi. (Biogen, a biotechnology company ...

The U.K.’s National Institute for Health and Care Excellence on Thursday again denied to recommend Biogen and Eisai’s Alzheimer’s disease therapy Leqembi, noting that its clinical benefits do not ...

Associations between biomarkers of poor synapse health and higher levels of Alzheimer’s-related proteins in the brain, as well as steeper… The U.S. Food and Drug Administration (FDA) has approved ...

Eisai Europe Ltd. and Biogen Idec Ltd. announced that NICE will convene a third appraisal committee meeting for the ongoing evaluation of Leqembi® (lecanemab ... in adult patients who are ...

Good morning everyone, it’s Jason Mast, filling in for Ed. Today I’m in Pharmalittle’s New York bureau, sipping a cup poured from a French press gifted to me by my sisters, made from beans ...

Simponi and Simponi Aria (golimumab) can cause mild to serious side effects. A more common side effect includes upper respiratory infection. If side effects from the drug become difficult to ...

Australia’s Therapeutic Goods Administration (TGA) has once again decided against approving Eisai Australia Pty Ltd.’s amyloid beta binder, Leqembi (lecanemab), for treating patients with mild ...

In October 2024, the TGA made the decision not to register lecanemab (LEQEMBI) on the Australian Register of Therapeutic ... and supervised by physicians with expertise in monitoring for ARIA. However ...

Biogen and Eisai said the European Medicines Agency's Committee for Medicinal Products for Human Use has reaffirmed its recommended approval of their Alzheimer's drug Leqembi. The companies on ...

Eisai has filed for approval of its Alzheimer’s disease therapy Leqembi in South Korea ... that seem to be more common in patients with ApoE ε4 mutations and among those taking anticoagulants ...

Specifically, your doctor will monitor your scans for amyloid-related imaging abnormalities (ARIA). This is because Leqembi treatment can cause ARIA. In fact, Leqembi has a boxed warning about the ...